BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Drug Development

  CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

  CytomX Therapeutics, Inc. announced positive initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-cancer activity.

  May 8, 2024

   · 

  9 min read
• Business

  Anika Announces CFO Transition - May 08, 2024

  Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that it has appointed Steve Griffin as the Company’s Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024.

  May 8, 2024

   · 

  6 min read
• Genetown

  Azenta Announces CEO Succession Plan

  Azenta, Inc. announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service.

  May 8, 2024

   · 

  3 min read
• Business

  Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.

  May 8, 2024

   · 

  11 min read
• Business

  QuidelOrtho Reports First Quarter 2024 Financial Results

  QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 31, 2024.

  May 8, 2024

   · 

  15 min read
• Business

  Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

  Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the first quarter of 2024 and provided a business update.

  May 8, 2024

   · 

  12 min read
• Business

  MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateConference Call to Begin Today at 5:00 p.m. (ET)

  MannKind Corporation reported financial results for the quarter ended March 31, 2024.

  May 8, 2024

   · 

  14 min read
• Business

  enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update

  enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today reported financial results for the first quarter 2024.

  May 8, 2024

   · 

  6 min read
• Business

  Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

  Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) today reported financial results for the first quarter ended March 31, 2024, and highlighted select corporate achievements.

  May 8, 2024

   · 

  11 min read
• Business

  SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

  SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2024.

  May 8, 2024

   · 

  9 min read